CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice
Yunching Chen(Kaohsiung Medical University), Dan G. Duda(Harvard University)
Cited by 456
Related Papers
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
|Angiogenesis|2017|690
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
|Journal of Clinical Oncology|2009|507